Neem leaf glycoprotein inhibits CD4 +CD25 +Foxp3 + Tregs to restrict murine tumor growth

Immunotherapy

Volumn 3, Issue 8, 2011, Pages 949-969

  Chakraborty, Tathagata ^a   Bose, Anamika ^b   Barik, Subhasis ^a   Goswami, Kuntal Kanti ^a   Banerjee, Saptak ^a   Goswami, Shyamal ^a   Ghosh, Diptendu ^a   Roy, Soumyabrata ^a   Chakraborty, Krishnendu ^c   Sarkar, Koustav ^d   Baral, Rathindranath ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b BOSE INSTITUTE   (India)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

CTLA4; Foxp3; neem leaf glycoprotein; Tregs

Indexed keywords

AZADIRACHTA INDICA EXTRACT; CHEMOKINE RECEPTOR CCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GLYCOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; MACROPHAGE DERIVED CHEMOKINE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR NFAT3; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AZADIRACHTA INDICA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CLONAL ANERGY; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; EHRLICH ASCITES TUMOR; FEMALE; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; LYMPHOCYTOTOXICITY; MELANOMA B16; MOUSE; NONHUMAN; PLANT LEAF; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD5; ANTINEOPLASTIC AGENTS; AZADIRACHTA; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL22; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FORKHEAD TRANSCRIPTION FACTORS; GLYCOPROTEINS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PLANT LEAVES; PLANT PROTEINS; RECEPTORS, CCR4; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 80051901440     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.81     Document Type: Article

References (52)

1. Sharma RK, Schabowsky RH, Srivastava AK et al. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res. 70, 3945-3954 (2010).
2. Kalinski P. Dendritic cells in immunotherapy of established cancer: roles of signals 1, 2, 3 and 4. Curr. Opin. Invest. Drugs 10, 526-535 (2009).
3. Cheng P, Corzo CA, Luetteke N et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205, 2235-2249 (2008).
4. Zhou G, Drake CG, Levitsky HI. Amplification of tumour-specific regulatory T cells following therapeutic cancer vaccines. Blood 107, 628-636 (2006). (Pubitemid 43076387)
5. Yang ZZ, Stephen MA. The role of Treg cells in the cancer immunological response. Am. J. Immunol. 5, 17-28 (2009).
6. Lim HW, Hillsamer P, Banham AH. Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J. Immunol. 175, 4180-4183 (2005). (Pubitemid 41361949)
7. Smyth MJ, Teng MW, Swann J. CD4+CD25+ T regulatory cells suppress NK cell mediated immunotherapy of cancer. J. Immunol. 176, 1582-1587 (2006). (Pubitemid 43134302)
8. Dai, Z, Li Q, Wang Y. CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J. Clin. Invest. 113, 310-317 (2004). (Pubitemid 38544215)
9. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211-5218 (1999).
10. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996). (Pubitemid 26102823)
11. Turk MJ, Guevara-Patiño JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200, 771-782 (2004). (Pubitemid 39299463)
12. Ghiringhelli F, Larmonier N, Schmitt E et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 4, 336-344 (2004). (Pubitemid 39255944)
13. Tchekmedyian S, Glasby J, Korman A, Keler T, Deo Y, Davis TA. MDX-010 (human anti-CTLA4): a Phase I trial in malignant melanoma. Proc. Am. Soc. Clin. Oncol. 21, Abstract 56 (2002).
14. Ribas A, Hanson DC, Noe DA et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. The Oncologist 12, 873-883 (2007). (Pubitemid 47328230)
15. Weberr J. Anti-CTLA-4 Antibody Ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12, 864-872 (2007).
16. Haque E, Mandal I, Pal S, Baral R. Prophylactic dose of neem (Azadirachta indica) leaf preparation restricting murine tumor growth is nontoxic, hematostimulatory and immunostimulatory. Immunopharmacol. Immunotoxicol. 28, 33-50 (2006). (Pubitemid 43739107)
17. Baral R, Mandal I, Chattopadhyay U. Immunostimulatory neem leaf preparation acts as an adjuvant to enhance the efficacy of poorly immunogenic B16 melanoma surface antigen vaccine. Int. Immunopharmacol. 5, 1343-1352 (2005). (Pubitemid 40725728)
18. Mandal-Ghosh I, Chattopadhyay U, Baral R. Neem leaf preparation enhances Th1 type immune response and anti-tumor immunity against breast tumor associated antigen. Cancer Immunity. 7, 8-17 (2007).
19. Sarkar K, Bose A, Chakraborty K et al. Neem leaf glycoprotein helps to generate carcinoembryonic antigen specific antitumor immune responses utilizing macrophage mediated antigen presentation. Vaccine 26, 4352-4362 (2008).
20. Baral R, Chattopadhyay U. Neem (Azadirachta indica) leaf mediated immune activation causes prophylactic growth inhibition of murine Ehrlich carcinoma and B16 melanoma. Int. Immunopharmacol. 4, 355-366 (2004). (Pubitemid 38375969)
21. Haque E, Baral R. Neem (Azadirachta indica) leaf preparation induces prophylactic growth inhibition of murine Ehrlich carcinoma in Swiss and C57BL/6 by activation of NK cells and NK-T cells. Immunobiology 211, 721-731 (2006). (Pubitemid 44464021)
22. Bose A, Baral R. NK cellular cytotoxicity of tumor cells initiated by neem leaf preparation is associated with CD40-CD40L mediated endogenous production of IL-12. Human Immunol. 68, 823-831 (2007). (Pubitemid 47599717)
23. Bose A, Chakraborty K, Sarkar K et al. Neem leaf glycoprotein induces perforin mediated tumor cell killing by T and NK cells through differential regulation of IFNg signaling. J. Immunother. 32, 42-53 (2009).
24. Bose A, Chakraborty K, Sarkar K et al. Neem leaf glycoprotein directs T-bet associated type 1 immune commitment. Hum. Immunol. 70, 6-15 (2009).
25. Goswami S, Bose A, Sarkar K, Roy S, Chakraborty T, Baral R. Neem leaf glycoprotein matures myeloid derived dendritic cells and optimizes anti-tumor T cell functions. Vaccine 28, 1241-1252 (2010).
26. Roy S, Goswami S, Bose A et al. Neem leaf glycoprotein partially rectifies suppressed dendritic cell functions and associated T cell efficacy in stage IIIB cervical cancer patients. Clin. Vac. Immunol. 18, 571-579 (2011).
27. Sarkar K, Goswami S, Roy S et al. Neem leaf glycoprotein enhances carcinoembryonic antigen presentation of dendritic cells to T and B cells for induction of antitumor immunity by allowing generation of immune effector/memory response. Int. Immunopharmacol. 10, 865-874 (2010).
28. Bose A, Haque E, Baral R. Neem leaf preparation induces apoptosis of tumor cells by releasing cytotoxic cytokines from human peripheral blood mononuclear cells. Phytother. Res. 21, 914-920 (2007). (Pubitemid 47582763)
29. Chakraborty K, Bose A, Pal S et al. Neem leaf glycoprotein restores the impaired chemotactic activity of peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients by maintaining CXCR3/CXCL10 balance. Int. Immunopharmacol. 8, 330-340 (2008).
30. Chakraborty K, Bose A, Chakraborty T et al. Optimum conditioning of dysregulated CC chemokine signaling for monocyte/ macrophage chemotaxis in head and neck squamous cell carcinoma patients by neem leaf glycoprotein maximizes tumor cell cytotoxicity. Cell. Mol. Immunol. 7, 396-408 (2010).
31. Komita H, Zhao X, Taylor JL et al. CD8+ T-cell responses against hemoglobin-b prevent solid tumor growth. Cancer Res. 68, 8076-8084 (2008).
32. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295-307 (2006).
33. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development andfunction of CD4+CD25+ regulatory T cells. Nat. Immunol. 4, 330-336 (2003). (Pubitemid 36432314)
34. Pallandr JR, Brillard E, Gilles Créhange G et al. Role of STAT3 in CD4+CD25+Foxp3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. J. Immunol. 179, 7593-7604 (2007).
35. Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kB to repress cytokine gene expression and effector functions of T helper cells. Proc. Natl Acad. Sci. 102, 5138-5143 (2005).
36. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat. Immunol. 9, 194-201 (2008).
37. Pandyan P, Lenardo MJ. The control of CD4+CD25+Foxp3+ regulatory T cell survival. Biol. Direct. 3, 6 (2008).
38. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949 (2004). (Pubitemid 39273735)
39. Colombo MP, Piconese S. Regulatory T-cells inhibition versus depletion: the right choice in cancer immunotherapy. Nat. Rev. Cancer. 7, 880-887 (2007). (Pubitemid 350006256)
40. Kitamura N, Murata S, Ueki T et al. OX40 costimulation can abrogate Foxp3+ regulatory T-cell-mediated suppression of antitumor immunity. Int. J. Cancer. 125, 630-638 (2009).
41. Yi T, Li X, Yao S et al. Host APCs augment in vivo expansion of donor natural regulatory T cells via B7H1/B7.1 in allergenic recipients. J. Immunol. 186, 2739-2749 (2011).
42. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2, 389-400 (2002). (Pubitemid 37328746)
43. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101, 455-458 (2000).
44. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 67, 371-380 (2007). (Pubitemid 46150755)
45. O'Mahony D, Morris JC, Quinn C et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin. Cancer Res. 13, 958-964 (2007). (Pubitemid 46340373)
46. Kavanagh B, O'Brien S, Lee D et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 112, 1175-1183 (2008).
47. Khan S, Burt DJ, Ralph C, Thistlethwaite FC, Hawkins RE, Elkord E. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clin. Immunol. 138, 85-96 (2011).
48. Reuben JM, Lee BN, Li C et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 106, 2437-2444 (2006). (Pubitemid 43787668)
49. Gabriel EM, Lattime EC. Anti-CTL-associated antigen 4, are regulatory T cells a target? Clin. Cancer Res. 13, 785-788 (2007).
50. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2, 3-dioxygenase activity in dendritic cells. J. Immunol. 172, 4100-4110 (2004). (Pubitemid 38375222)
51. Maker AV, Phan GQ, Attia P. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol. 12, 1005-1016 (2005). (Pubitemid 41660676)
52. Chakraborty T, Bose A, Chakraborty K et al. Suppression of suppressors: neem leaf glycoprotein guided crosstalk between regulatory T cells and T cells/NK cells/ macrophages in cancer. In:Treatments of Advanced Stage Cancers: Current Status and Emerging Frontiers . Talwar GP, Sood OP (Eds).Narosa Publishing House, India, 153-157 (2009).